Common Contracts
8 similar Underwriting Agreement contracts by Adma Biologics, Inc., Federated National Holding Co, PLx Pharma Inc., PLX Pharma Inc.
7,875,000 Shares1 PLx Pharma Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 3rd, 2021 • PLx Pharma Inc. • Pharmaceutical preparations • New York
PLx Pharma Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 7,875,000 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 7,875,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 1,181,250 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
8,368,200 Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 8th, 2018 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 8,368,200 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 8,368,200 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 1,255,230 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
16,976,744 Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 9th, 2017 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 16,976,744 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 16,976,744 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 2,546,511 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
●] Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 3rd, 2017 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [●] shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of [●] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [●] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
1,892,308 Shares* ADMA Biologics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 28th, 2016 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York
ADMA Biologics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,892,308 shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of 1,892,308 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 283,846 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
Shares* PLx Pharma Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 15th, 2016 • PLX Pharma Inc. • Pharmaceutical preparations • New York
PLx Pharma Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [__________] shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of [_______] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [________] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. (“RJ&A”) is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
2,051,283 Shares* FEDERATED NATIONAL HOLDING COMPANY Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 1st, 2014 • Federated National Holding Co • Fire, marine & casualty insurance • Florida
Federated National Holding Company, a Florida corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 2,051,283 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 2,051,283 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 307,692 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
2,418,605 Shares* FEDERATED NATIONAL HOLDING COMPANY Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 20th, 2013 • Federated National Holding Co • Fire, marine & casualty insurance • Florida
Federated National Holding Company, a Florida corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 2,418,605 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 2,418,605 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 362,790 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
